EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Immunogenicity Assessment of an Engineered Recombinant PspA Protein: A 10-Month Humoral Response

Farzaneh Sadat Sajadpour, Fatemeh Kazemi-Lomedasht, Hoda Jahandar, Alireza Erfani, Sheyda Mohammadkhani, Mahdi Habibi-Anbouhi

Protein & Peptide Letters · 2026-11

DOI: 10.1016/j.ppl.2026.11.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Protein & Peptide Letters, 2026-11. Verfasst von Farzaneh Sadat Sajadpour und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran; Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Pharmaceutic…. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Streptococcus pneumoniae is a major cause of serious infections, including pneumonia. Pneumococcal surface protein A (PspA), a surface-exposed virulence-associated protein, is a promising vaccine target. This study evaluated the persistence and specificity of the humoral immune response induced by recombinant engineered PspA antigen ABC4 in mice.

Methods

Ten female BALB/c mice (6-8 weeks old, 16-22 g) were randomly allocated to an ABC4-immunized group or an adjuvant control group, with five mice initially assigned to each group. One mouse from each group was subsequently lost, leaving four mice per group for the final analysis. The experimental group received ABC4 with Alum, while controls received saline with Alum. Serum samples were collected before and after immunization and during follow-up for up to 10 months after the final immunization. Antigen-reactive antibody responses were assessed semi-quantitatively by ELISA at a single serum dilution (1: 500), with results expressed as OD 450 values. Western blotting evaluated IgG recognition of recombinant ABC4 and proteins present in native S. pneumoniae preparations.

Results

ABC4 immunization induced a marked increase in relative antibody levels, which remained relatively stable for six months and detectable at 8 and 10 months after the final immunization. Mean OD 450 values decreased by approximately 23% between 6 and 10 months. Western blotting demonstrated IgG recognition of recombinant ABC4 and proteins present in S. pneumoniae serotypes 19A and 19F, indicating reactivity toward native pneumococcal proteins. The detected proteins migrated at approximately 70-75 kDa; however, their identity as PspA could not be definitively established.

Conclusions

ABC4 induced a persistent humoral immune response detectable for up to 10 months in female BALB/c mice, with IgG recognition of recombinant ABC4 and native pneumococcal proteins. Given the semi-quantitative ELISA, absence of endpoint titration and functional antibody assays, and lack of challenge experiments, the findings support further preclinical evaluation rather than conclusions regarding protective immunity.

Schlagwörter

Stichwörter der Autor:innen

ImmunizationPneumococcal surface protein APspAStreptococcus pneumoniaeVaccine candidatepneumonia

Autor:innen und Institutionen

  • National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran; Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran,…
  • Venom and Biotherapeutics Molecules Laboratory, Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
  • Pharmaceutical Sciences Research Center, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran.
  • National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran.
  • National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran. Electronic address: habibi.mha@gmail.com.

Zitieren

APA

Sajadpour, F. S., Kazemi-Lomedasht, F., Jahandar, H., Erfani, A., Mohammadkhani, S., & Habibi-Anbouhi, M. (2026). Immunogenicity Assessment of an Engineered Recombinant PspA Protein: A 10-Month Humoral Response. Protein & Peptide Letters. https://doi.org/10.1016/j.ppl.2026.11.002

Vancouver

Sajadpour FS, Kazemi-Lomedasht F, Jahandar H, Erfani A, Mohammadkhani S, Habibi-Anbouhi M. Immunogenicity Assessment of an Engineered Recombinant PspA Protein: A 10-Month Humoral Response. Protein & Peptide Letters. 2026. doi:10.1016/j.ppl.2026.11.002

BibTeX
@article{Sajadpour2026,
  author = {Sajadpour, Farzaneh Sadat and Kazemi-Lomedasht, Fatemeh and Jahandar, Hoda and Erfani, Alireza and Mohammadkhani, Sheyda and Habibi-Anbouhi, Mahdi},
  title = {Immunogenicity Assessment of an Engineered Recombinant PspA Protein: A 10-Month Humoral Response},
  journal = {Protein & Peptide Letters},
  year = {2026},
  doi = {10.1016/j.ppl.2026.11.002}
}
Kostenlos starten →